Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for relugolix/estradiol/norethisterone acetate

  1. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  2. Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

  3. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

  4. Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 22 April 2024.

  5. Past appeals and decisions

    September 2000 TA032 Multiple sclerosis - beta interferon and glatiramer acetate 26 November 2001 TA218 Myelodysplastic syndrome -...

  6. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  7. Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE

    Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.